About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
https://www.weizmann-usa.org/news-media/feature-stories/p53-and-personalized-medicine/
Jan 06, 2010...
As a postdoctoral researcher at the Massachusetts Institute of Technology (MIT) 30 years ago, Prof. Varda Rotter was among the first scientists to study a little-known gene called p53. "We didn't know then that it was going to turn out to be so important for cancer research," she says.
It was during those early days of her research in the laboratory of microbiologist and Nobel laureate David Baltimore that she realized, she says, "that science is one of the most exciting things one can do—you can really pursue your dreams."
Oct 15, 2019...
Your body is composed of about 10 million human cells. It’s also home to about 100 trillion tiny microbes, mainly bacteria, that wield astonishing power over your health.
Many influences, from genetics, to diet and stress, contribute to the makeup of your microbiome — the collective community of microbes as personal as a fingerprint.
Understanding, manipulating and balancing the microbiome could play an increasing role in preventing and curing diseases.
Jun 02, 2007... Prof. Doron Lancet of the Department of Molecular Genetics at the Weizmann Institute of Science is one of Israel's most prominent genome researchers. The head of the Crown Human Genome Center, Prof. Lancet has directed research on DNA chips, disease genes, and genes responsible for smell and taste, and is currently working to develop a computational model for the origin of life on earth. Because the Weizmann Institute was Israel's liaison to the international Human Genome Project, Prof. Lancet and his colleagues have unusually intimate knowledge of the field of genomics and its implications.
Jun 07, 2006...
Between April 2004 and February 2005, 28 men with prostate cancer showed up at three Canadian hospitals for one-time injections of an experimental drug designed to eradicate their deadly tumors. Radiation had already failed them.
By December tumors in the earliest-treated patients had shrunk by as much as 84%. But the real test began in March, when doctors started studying tissue samples. If they find the tumors are gone or reduced to a manageable level, it may indicate that the drug is reliable over time, and researchers could be on their way to a radical advancement in localized prostate cancer treatment.
Jan 28, 2010...
Alone they may be ineffective, but used together two common antibiotics could fight off deadly antibiotic-resistant superbugs, according to a team of Israeli and American researchers.
Two pills are better than one: Israeli Prof. Ada Yonath and her researchers have discovered that a combination of two antibiotics can fight antibiotic resistant diseases.
Researchers from Israel and the US have discovered that two marginally useful antibiotics working together could be more effective in fighting off today’s deadly antibiotic-resistant superbugs than either drug working alone.
Mar 22, 2012... Procognia (TASE:PRCG) is pleased to announce that the feasibility stage of the research, which focused on the glycosylation structures of stem cells, has been successfully completed. The research, directed by Prof. Dov Zipori from the Weizmann Institute of Science, was designed to develop a platform that will significantly improve the ability to identify and develop unique stem cells for transplant and treatment. Today, stem cell treatment faces a number of challenges, which both parties aim to handle successfully and therefore make a significant contribution to this field.
https://www.weizmann-usa.org/news-media/in-the-news/coming-soon-a-vaccine-against-cancer/
Apr 17, 2011...
Holding out hope of a vaccine for some of today's deadliest diseases — Vacciguard CEO Dr. Anat Eitan.
The notion of a vaccine for cancer—or for many other deadly diseases nearly impossible to control, let alone cure—may seem to be no more than wishful thinking. But that is exactly what Israeli biomed startup Vacciguard is introducing: A technology tool for developing vaccines against a wide range of diseases from cancer to West Nile virus.
Aug 04, 2009... REHOVOT, ISRAEL—August 3, 2009—Biomolecular computers, made of DNA and other biological molecules, only exist today in a few specialized labs, remote from the regular computer user. Nonetheless, Tom Ran and Shai Kaplan, research students in the lab of Prof. Ehud Shapiro of the Weizmann Institute's Biological Chemistry, and Computer Science and Applied Mathematics Departments have found a way to make these microscopic computing devices "user friendly," even while performing complex computations and answering complicated queries.
Nov 30, 2017... Toward Healthy Aging: The Sagol Institute of Longevity
https://www.weizmann-usa.org/blog/the-gender-of-medication/
Jul 29, 2020...
You wouldn’t give a toddler the same dose of ibuprofen that you, an adult – let’s assume you’re a woman – take. Likewise, should your dose be the same as a man’s?
It’s so clear when you take a moment to consider it; in the article “Should medicine be gendered?” (which also cites Weizmann Institute research), the BBC’s Science Focus nutshells it for us: “Men and women have completely different biologies, and yet doctors prescribe the same drugs and doses to everyone, regardless of sex.”
©2023 American Committee for the Weizmann Institute of Science
